Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Daunorubicin hydrochloride
Drug ID BADD_D00592
Description A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Indications and Usage For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Marketing Status approved
ATC Code L01DB02
DrugBank ID DB00694
KEGG ID D01264
MeSH ID D003630
PubChem ID 62770
TTD Drug ID D01XWG
NDC Product Code 42658-021; 0143-9551; 53183-1447; 42658-019; 0143-9550; 58623-0046; 17337-0067
UNII UD984I04LZ
Synonyms Daunorubicin | Daunomycin | Rubomycin | Dauno-Rubidomycine | Dauno Rubidomycine | Rubidomycin | Daunoblastin | Daunoblastine | NSC-82151 | NSC 82151 | NSC82151 | Cerubidine | Daunorubicin Hydrochloride | Hydrochloride, Daunorubicin
Chemical Information
Molecular Formula C27H29NO10.HCl
CAS Registry Number 23541-50-6
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O. Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Cellulitis11.02.01.001; 23.11.02.004---
Chills08.01.09.001; 15.05.03.016--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004---
Diarrhoea07.02.01.001--
Extravasation08.01.03.008---
Hyperuricaemia14.09.01.003--
Injection site induration08.02.03.007; 12.07.03.007---
Mucosal inflammation08.01.06.002---
Nausea07.01.07.001--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Thrombophlebitis24.01.02.001---
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Cardiotoxicity02.11.01.009; 12.03.01.007---
Bone marrow failure01.03.03.005--
Soft tissue necrosis15.03.02.002; 24.04.02.007--
The 1th Page    1    Total 1 Pages